Medtronic makes $90M strategic investment in Anteris; combined $320M capital raise

Anteris Technologies Global Corp.

Medtronic invested $90M in Anteris via stock purchase; Anteris also completed an underwritten common stock offering for total gross proceeds of $320M.
Proceeds to fund global pivotal PARADIGM trial and global commercialization of DurAVR THV (transcatheter heart valve).
PARADIGM trial is a randomized controlled trial of ~1000 patients comparing DurAVR THV to commercially available TAVRs; enrollment started Q4 2025.
Medtronic and Anteris may expand collaboration into other strategic areas; Medtronic joins Anteris' stockholder community.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.